These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38813782)

  • 21. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Palmar-plantar erythrodysesthesia syndrome resulting from toceranib phosphate in a dog with apocrine gland anal sac adenocarcinoma: a case report.
    Kim E; Kim SS; Ryu MO
    J Vet Sci; 2023 Nov; 24(6):e76. PubMed ID: 37904638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.
    Harris CS; Wang D; Carulli A
    J Oncol Pharm Pract; 2014 Feb; 20(1):73-80. PubMed ID: 23478198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Shiraishi Y; Kishimoto J; Tanaka K; Sugawara S; Daga H; Hirano K; Azuma K; Hataji O; Hayashi H; Tachihara M; Mitsudomi T; Seto T; Nakagawa K; Yamamoto N; Okamoto I
    Clin Lung Cancer; 2020 Sep; 21(5):472-476. PubMed ID: 32381420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological Agents for Treating Atezolizumab-Induced Psoriasis in Small-Cell Lung Cancer: A Case Report.
    Fukui M; Chihara Y; Takahashi Y; Sai N; Doi H; Nakakubo Y; Saito M
    Cureus; 2024 May; 16(5):e61395. PubMed ID: 38947665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological Complete Response after Immune-Checkpoint Inhibitor Followed by Salvage Surgery for Clinical Stage IV Pulmonary Adenocarcinoma with Continuous Low Neutrophil-to-Lymphocyte Ratio: A Case Report.
    Higuchi M; Kawamata T; Oshibe I; Soeta N; Saito T; Hojo H; Matsumura Y; Suzuki H
    Case Rep Oncol; 2021; 14(2):1124-1133. PubMed ID: 34413743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Rare Case Presentation of Vitiligo Associated With Atezolizumab.
    Nwanwene K; Abdallah M; Pacioles T
    J Investig Med High Impact Case Rep; 2023; 11():23247096231154640. PubMed ID: 36748760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
    Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
    Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
    Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
    Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
    Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy.
    Nakai M; Kai Y; Suzuki K; Matsuda M; Kikukawa S; Masuda H; Soga M; Ueda T; Yoshimura A; Takano M; Hontsu S; Uno K; Muro S
    Respir Med Case Rep; 2023; 41():101794. PubMed ID: 36583058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised controlled feasibility trial to evaluate Lawsonia inermis (henna)'s effect on palmar-plantar erythrodysesthesia induced by capecitabine or pegylated liposomal doxorubicin.
    Stavrinou M; Tsitsi T; Astras G; Paikousis L; Charalambous A
    Eur J Oncol Nurs; 2021 Apr; 51():101908. PubMed ID: 33626423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atezolizumab-Induced Lambert-Eaton Myasthenic Syndrome in a Patient With Small-Cell Lung Cancer.
    Yamazoe M; Hatakeyama T; Furukawa K; Kato K; Horiuchi K
    Cureus; 2023 Jan; 15(1):e33557. PubMed ID: 36779131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
    Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
    BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
    Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
    J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photobiomodulation in the treatment of palmar-plantar erythrodysesthesia: a randomised controlled clinical study protocol.
    Lestido V; Rodríguez F; Rodríguez A; Pombo V; Barrios R; Pavani C
    BMJ Open; 2024 Apr; 14(4):e081459. PubMed ID: 38657999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis.
    Lu W; Zhang H; Guo Q; Gou Z; Yao J
    Front Pharmacol; 2023; 14():1076473. PubMed ID: 37332342
    [No Abstract]   [Full Text] [Related]  

  • 39. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oleosomes Encapsulating Sildenafil Citrate as Potential Topical Nanotherapy for Palmar Plantar Erythrodysesthesia with High Ex vivo Permeation and Deposition.
    Abdelalim LR; Elnaggar YSR; Abdallah OY
    AAPS PharmSciTech; 2020 Nov; 21(8):310. PubMed ID: 33164131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.